The event that really changed ABL Bio’s global standing was a technology transfer deal worth around $1.06 billion that it inked with Paris-based health care company Sanofi in January for ABL301, a treatment candidate for degenerative brain diseases such as Parkinson’s disease that is currently undergoing preclinical trials.
youtube.com/watch?v=nM3X_U1...
Has there been any further process with ABL301? Do you have other drugs that are waiting to start clinical trials?
ABL301 is set to start Phase 1 clinical trials at the end of the year. As the CEO, I'm hoping to announce some kind of good news in the second half.
Also, two other candidates, ABL101 and ABL103, are expected to enter trials next year. ABL105, an anticancer drug candidate targeting solid tumors, is expected to start Phase 1 clinical trials soon by Yuhan. Yuhan signed a licensing deal for the candidate in 2018.
We aim to have at least two candidates that start clinical trials every year.
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE
2021 Should be An Informative Year
Inhibikase IkT-148009 Phase 2: the study record on the Clinical Trials website has had a small, but significant, update.
First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson's 
